Immune-modified Glasgow prognostic score: A new prognostic marker for head and neck cancer.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 36054630.
- Also identified by DOI 10.1002/hed.27170.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The modified Glasgow prognostic score (mGPS) includes C-reactive protein and serum albumin levels and is a useful prognostic tool for malignant tumors. The immune system affects cancer progression and recurrence and treatment response. We hypothesized that increasing the lymphocyte count improves mGPS, and we created a new prognostic marker termed immune-mGPS (imGPS). This study included 461 patients with head and neck squamous cell carcinoma (HNSCC). The imGPS was calculated as the conventional mGPS with one additional point for a low lymphocyte count (<1250/μL). Addition of the lymphocyte count to mGPS significantly increased the area under the time-dependent receiver operating characteristic curve for overall and progression-free survivals. The added predictive abilities of this tool were supported by improvement in both net reclassification and integrated discrimination. imGPS is a more accurate predictor of clinical outcome in patients with HNSCC than mGPS.
Medical subject headings
- C-Reactive Protein
- Head and Neck Neoplasms